Open an account

Roche Holding AG

RHHVF · SWISS

$475.00+$16.91 (+3.69%)TodayMarket closed ·
Prev close $458.09

About RHHVF

Roche Holding AG is a research healthcare company. The company is headquartered in Basel, Basel-Stadt and currently employs 112,774 full-time employees. The company went IPO on 2001-05-04. The firm's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The firm develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The firm offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.

Employees
112,774
Headquarters
Basel, Basel-Stadt
Listed
May 4, 2001
Sector
Health Care
Industry
Pharmaceuticals
Website
roche.com

RHHVF key statistics

Market cap
302.27B
Price-earnings ratio
0.00
Dividend yield
2.88%
Average volume
3.76K
Volume
1.19K
Open price
$466.00
High today
$475.00
Low today
$460.78
52 Week high
$490.33
52 Week low
$318.81

Roche Holding AG (RHHVF) at a glance

As of Oct 20, 2026, Roche Holding AG (RHHVF) shares are priced at $475.00, giving the company a market cap of 302.27B, a price-to-earnings ratio of 0.00 and a dividend yield of 2.88%.

Today the stock has traded between $460.78 and $475.00. The current price is 3.1% above the day's low and 0.0% below its high.

Volume so far is 1.19K shares, below the average of 3.76K shares a day.

Over the past year Roche Holding AG has ranged from $318.81 to $490.33, and now sits 91% of the way up that range.

Roche Holding AG met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported $10.85 per share against an estimate of $10.38.

RHHVF earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 4.2% on average.

  1. Q4 FY22: reported $8.54 per share against an estimate of $8.90
  2. Q2 FY23: reported $10.10 per share against an estimate of $10.36
  3. Q4 FY23: reported $8.47 per share against an estimate of $8.49
  4. Q2 FY24: reported $10.23 per share against an estimate of $9.34
  5. Q4 FY24: reported $8.57 per share against an estimate of $8.48
  6. Q2 FY25: reported $11.10 per share against an estimate of $10.94
  7. Q4 FY25: reported $8.53 per share against an estimate of $8.84
  8. Q2 FY26: reported $10.85 per share against an estimate of $10.38

RHHVF news

  • Press releasePRNewswire

    New survey demonstrates how diabetes limits day-to-day freedom for people around the world and highlights need for predictive tools

Similar companies

Companies in the same industry as Roche Holding AG

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.